



EVITRADE Announces Binding LOI to Acquire Hemp Extraction Technology Corp. And Continued Engagement with Haywood Securities Inc.

VANCOUVER, BC, Friday October 5, 2018 – EVITRADE Health Systems Corp. (CSE: EVA, OTCQB: EVAHF) (the “Company” or “Evitrade”) announces the agreement of terms for a binding letter of intent (“LOI”) to acquire Hemp Extraction Technology Corp. (“HETC”).

“We look forward to working with HETC to bring their extraction technology and expertise to the Company that is a critical component in ensuring and delivering medical grade ingredients for the company’s health technology developments” said C.K. Cheung.

Closing of the LOI with Hemp Extraction Technology Corp. is subject to Evitrade completing due diligence with HETC to and to complete the transaction (the “Proposed Transaction”) whereby Evitrade will acquire all of the outstanding share of HETC in exchange for an aggregate of up to 23,333,333 shares of Evitrade issued at the deemed price of \$0.30 per share. The result of the Proposed Transaction would be that HETC would become a wholly-owned subsidiary of Evitrade.

In addition the company announces that it had continued its advisory services arrangement with Haywood Securities Inc. and has issued 1,000,000 shares in conjunction with the agreement.

Management continues to strive to seek optimal business and commercialization strategies for the Company. Full details of the transaction will be available subsequent to closing on the definitive agreement.

Contact: C.K. Cheung, CEO & Director

EVITRADE Health Systems Corporation
(formerly Auxellence Health Corporation)

Email info@evahealthsystems.com

Website <http://www.evahealthsystems.com>

CSE Micro-site: <http://thecse.com/en/listings/technology/evitrade-health-systems-corp>

US OTC Markets (OTCQB): <http://www.otcmarkets.com/stock/EVAHF/news>

About EVITRADE Health (CSE: EVA, OTCQB: EVAHF)

EVITRADE Health Systems Corp. (formerly Auxellence Health Corp.), is a Technology company specializing in the Life Sciences sector looking to deliver effective health solutions with a higher degree of predictability and consistency.

The Company is focused in four main areas, Autonomous Medical Care, Molecular Biology, Nutritional Solutions and Genetic Selection. Through its Focus on Autonomous Medical Care, the Company offers a physiologically interactive computing platform that integrates medical devices and artificial intelligence applications into a fully automated, personal health management system for hypertension, arrhythmia, diabetes, and obesity.

Disclaimers – Forward Looking Statements

This news release contains forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s

Discussion and Analysis and other disclosure filings with Canadian securities regulators and on the OTC Markets website which is posted on www.sedar.com, <http://thecse.com/en/listings/technology/evitrade-health-systems-corp>, and <https://www.otcm Markets.com/stock/EVAHF/news> . This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.